A medium throughput rodent model of relapse from addiction with behavioral and pharmacological specificity by Eiler, William J. A., II et al.
AC
CE
PT
ED
 M
AN
US
CR
IPT
Elier et al – mGlu5 receptors and relapse 
A medium throughput rodent model of relapse from 
addiction with behavioral and pharmacological specificity 
William J.A. Eiler II
1,2
, Scott D. Gleason
2
, Jodi L. Smith
3
, and Jeffrey M. Witkin
2,4,5
1
Department of Psychology 
Franklin College, Franklin Indiana USA 
2
Neuroscience Discovery 
Lilly Research Labs, Indianapolis Indiana USA 
3
Laboratory of Antiepileptic Drug Discovery, 
St. Vincent’s Hospital, Indianapolis, Indiana USA 
4
Department of Neurological Surgery 
Indiana University School of Medicine, Indianapolis Indiana USA 
5
Department of Chemistry & Biochemistry 
University of Wisconsin-Milwaukee, Milwaukee Wisconsin USA 
Correspondence to: 
   Jeffrey M. Witkin, Ph.D.  
 Witkin Consulting Group 
 Carmel, Indiana 46033 USA 
(317) 933-1167
witkinconsult@gmail.com
ACCEPTED MANUSCRIPT
___________________________________________________________________
This is the author's manuscript of the article published in final edited form as:
Eiler, W. J. A., Gleason, S. D., Smith, J. L., & Witkin, J. M. (2019). A medium throughput rodent model of relapse 
from addiction with behavioral and pharmacological specificity. Pharmacology Biochemistry and Behavior. 
https://doi.org/10.1016/j.pbb.2019.06.005
AC
CE
PT
ED
 M
AN
US
CR
IPT
Elier et al – mGlu5 receptors and relapse   2 
 
Document Statistics 
   Abstract: 225 words 
   Tables: 1 
   Figures: 4 
 
 
 
Non-standard Abbreviations 
 
ABT-431- diacetyl prodrug form of (5 a R, 11 b S)-4,5,5a,6,7,11b-hexahydro-2 propyl-3-
thia-5-azacyclopent-1-ena[c]-phenanthrene-9,10-diol (A-86929) 
 
FR1 – fixed-ratio 1 
 
LY379268 - (1R,4R,5S,6R)-4-Amino-2-oxabicyclo[3.1.0]hexane-4,6-dicarboxylic acid 
 
MPEP - 2-Methyl-6-(phenylethynyl)pyridine 
 
MTEP - 3-((2-Methyl-4-thiazolyl)ethynyl)pyridine 
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ABSTRACT 
 One of most formidable problems in the treatment of addiction is the high rate of 
relapse. The discovery of medicines to help mitigate relapse are aided by animal models 
that currently involve weeks of training and require surgical preparations and drug 
delivery devices.  The present set of experiments was initiated to investigate a rapid 8-
day screening method that utilizes food instead of intravenous drug administration. Male 
Sprague-Dawley rats were trained in a reinstatement paradigm in which every lever press 
produced a 45mg food pellet concurrently paired with a light and tone.  Behavior was 
subsequently extinguished with lever responses producing neither food nor food-
associated stimuli.  Reinstatement of responding was evaluated under conditions in which 
the first three responses of every 5 min time bin produced a food pellet along with food-
associated stimuli.  The mGlu5 receptor antagonists MPEP and MTEP produced a 
significant reduction in reinstatement while failing to alter responding where every 
response produced food. The cannabinoid CB1 receptor antagonist rimonabant and the 
mGlu2/3 receptor agonist LY379268 also selectively reduced reinstatement. Other 
compounds including clozapine, d-amphetamine, chlordiazepoxide, ABT-431, naltrexone 
and citalopram were without effect.  The results suggest that relapse-like behavioral 
effects can be extended to non-pharmacological reinforcers.  Drug effects demonstrated 
both behavioral and pharmacological specificity.  The present experimental design thus 
allows for efficient and rapid assessment of the effects of drugs that might be useful in 
the treatment of addiction-associated relapse. 
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INTRODUCTION 
 One of most formidable problems in the treatment of addiction is the high rate of 
relapse following periods of prolonged abstinence (Hunt et al. 1971; O’Brien 1997).  In 
humans, initiation of drug-taking behavior following abstinence is typically preceded by 
craving for the abused drug.  Motivation to re-engage patterns of drug-seeking and drug-
taking can be produced by the drug itself or by the presentation of stimuli associated with 
drug taking behavior (Wikler, 1973; Wikler and Pescor, 1967).   
Initial work on the creation of an animal model of human drug relapse began over 
three decades ago with the seminal work of Stretch and colleagues (1971) and Davis and 
Smith (1976).  Little has changed since the emergence of the paradigm with the basic 
methodology remaining essentially the same.  Animals are first trained to produce 
responses by reinforcing those responses by drug infusion.  Following acquisition of 
drug-taking, the behavior is extinguished by removal of the drug and drug-associated 
stimuli.  Drug-seeking behavior is then reinstated by the presentation of a reinstatement 
trigger that can include exposure to the drug itself or drug associated stimuli (Jaffe et al. 
1989; Ludwig et al. 1974; O’Brien et al. 1992) or the presence of a stressor (Brown et al. 
1995; Sinha, 2001).  Each of these factors has been shown to produce self-reports of 
craving andrelapse in abstinent humans (Childress et al., 1999; Robbins et al., 1999; 
Walsh et al., 2000; Wasserman et al., 1998). 
Animal models of relapse generally use intravenous drugs as reinforcers requiring 
surgical preparations and drug delivery devices.  In addition, these relapse models require 
long training periods before novel potential anti-craving compounds can be evaluated.  
For example, Kim et al. (2015) used intravenous cocaine administration requiring 
surgical implantation of indwelling intravenous catheters followed by recovery time, 12 
days of cocaine self-administration training, followed by 9 days of extinction training.  In 
the present set of experiments, we utilize food as a reinforcer in a paradigm that allows 
anti-relapse drug testing in 8 days.  The idea behind this method is the overlap in 
functional behavioral and biological substrates for reinforced behaviors that transcend the 
specific reinforcing stimulus (drug or food).   
Commonalities in the functional control of behavior by diverse reinforcers have 
been demonstrated (Kelleher and Morse, 1968; Barrett, 1987; Witkin and Katz, 1990).  It 
is increasingly recognized that the behavioral bases and biological substrates underlying 
addictions of drug- and non-drug stimuli share common ground (c.f., Chamberlain et al., 
2016; Chen et al., 2017; Rogers, 2017; Volkow et al., 2012, 2017).  Nonetheless, the 
generality of relapse phenomenon to non-drug reinforcers has undergone little 
experimental scrutiny.   Studies have shown that stimuli associated with either food 
reward or pharmacological reinforcers can produce motivation to seek out and to  crave 
these reinforcers (Brody et al., 2002; Childress et al., 1999).  Such a motivational state is 
what is thought to produce relapse not only to drug-taking behavior, but as Berthoud 
(2004) suggests, relapse to feeding as well. For example, the anxiogenic drug, yohimbine, 
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can reinstate behavior following a period of extinction in animals previously trained to 
self-administer food just as it has after drug reinforcers (Ghitza et al., 2006).  
The over-arching goal of the present study was to evaluate the utility of a new 
animal model of food reinstatement developed from modifications of the classic drug-
reinstatement paradigms.  We first established the reliability of generating reinstatement 
of extinguished behavior after only 8 days.  Next, we determined the relative efficacy of 
different conditions to induce reinstatement of behavior.  Subsequently, several drugs 
were tested under these conditions to assess their ability to dampen reinstated behavior.  
The drugs selected were based upon those used in patients and those suggested to be anti-
craving drugs in the preclinical scientific literature.   These drug effects were compared 
to effects of other compounds that are generally not thought of as anti-craving 
medications.  Thus, these pharmacological studies begin to ascertain 1) whether the 8-day 
model has predictive validity for detecting anti-relapse drugs and rejecting drugs that are 
not applicable for anti-relapse therapeutics, and 2) whether a food-based reinstatement 
model detects comparable pharmacological mechanisms to those detected with drug 
reinforcer-based models.  In addition to beginning to define pharmacological specificity 
in this model, we utilized control behaviors (non-reinstated behaviors) to determine if the 
drug effects on reinstatement are behaviorally specific.  It is argued that drugs that 
dampen relapse behaviors at doses that do not affect the non-relapse behaviors should be 
considered as specific pharmacological mechanisms for relapse prevention.   
Drugs that have some validation as anti-craving medications selected for 
investigation are briefly outlined here.  The CB1 receptor antagonist rimonabant, that has 
been used as an anti-obesity drug (Rubio et al., 2007) was predicted to reduce craving 
(Kirkham, 2008) and has demonstrated reductions in hunger in humans (Koch et al., 
2017) and craving in animal models of reinstatement (Cohen et al., 2005; De Vries et al., 
2001; Piomelli, 2001; Schindler et al., 2016; Ward et al., 2009).  In addition to opioid 
abuse disorders, naltrexone is used in the treatment of alcohol addiction where it reduces 
craving in humans (Hendershot et al., 2017) and attenuates reinstatement to some drugs 
of abuse in animal models (Anggadiredja et al., 2004; Ciccocioppo et al., 2003; Liu and 
Weiss, 2002).   
Dampening of glutamate neurotransmission by mGlu5 receptor antagonism has 
been suggested as an anti-relapse mechanism from reinstatement studies in rodents 
(Bäckström et al., 2004; Bespalov et al., 2005; Kim et al., 2015; Knackstedt and 
Schwendt, 2016; Pomierny-Chamiolo et al., 2017a; Richard, 2019; Tessari et al., 2004).  
Likewise, reducing glutamate outflow by mGlu2/3 receptor agonists has also been shown 
to be an effective method of reducing reinstated behaviors in rodent models (Baptista et 
al., 2004; Pomierny-Chamiolo et al., 2017b) or in primates (Justinova et al., 2016).  Drugs 
that are not considered to have anti-craving properties were studied for comparison: the 
antipsychotic drug clozapine, the psychostimulant, d-amphetamine, the anxiolytic drug 
chlordiazepoxide, the antidepressant citalopram, and the dopamine receptor agonist ABT-
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431.  Although some justification is provided for the compounds used for assay 
validation in the present study, it is recognized that until there are medicines proven for 
their efficacy against drug abuse relapse and/or food-related behaviors, these tools remain 
imperfect.  The validation of predictive animal models depends upon existing and 
emerging data gained from controlled studies from both the preclinical and clinical 
laboratories that reciprocally inform one another (Willner, 1984). 
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MATERIALS AND METHODS 
 
Subjects.  Male Sprague-Dawley rats (Harlan Sprague-Dawley, Indianapolis, IN, USA) 
weighing 275-305 g upon arrival were used for all phases of this study.  A total of 475 
rats were used in these experiments.  These animals were housed individually to allow for 
food restriction to produce animals weighing ~85% of their free feeding weight.  All 
animals were fed daily. While food was restricted, all animals had free access to water.  
All animals were placed on a normal light/dark cycle with lights on at 6:00 am and off at 
6:00 pm with experiments conducted between 9:00 am and 4:00 pm.  Animals were 
removed from the vivarium in their home cages and transported to the testing room.  All 
experiments were conducted according to the Guidelines for Care and Use of Laboratory 
Animals under protocols approved by a local animal care and use committee and under 
monitoring by veterinary staff. 
 
Apparatus.  Animals were tested in 14 standard rat operant chambers (Med Associates, 
Inc, St. Albans, VT, USA) equipped with 2 levers on a single wall with a pellet delivery 
assembly with the food trough located between the levers (see Alt et al., 2005). Each 
chamber was also equipped with a house light, as well as white cue lights above each 
lever and an audio tone generator (sonalert @4500 Hz and 65dB).  The grid floor of the 
chamber enabled delivery of scrambled electric shock.   
 
Drugs and Food Pellets.  A number of psychoactive drugs were tested in this study in 
order to evaluate the dynamics of the new reinstatement paradigm.  These drugs include 
the antipsychotic clozapine, the benzodiazepine anxiolytic chlordiazepoxide, the 
dopamine D1 receptor agonist ABT-431, the dopamine releaser d-amphetamine, the pan 
opioid receptor antagonist naltrexone, and the selective serotonin reuptake inhibitor 
citalopram which were purchased from Sigma Chemical Company (St. Louis, MO).  We 
also studied, the cannabinoid CB1 receptor antagonist SR141716A (rimonabant), the 
mGlu2/3 receptor agonist LY379268, and the mGlu5 receptor antagonists MPEP and 
MTEP which were synthesized at the Lilly Research Labs.  All agents were administered 
via intraperitoneal (i.p.) injection 30 min before the start of the test session in an injection 
volume of 1.0 ml/kg.  Clozapine, chlordiazepoxide, ABT-431, LY379268, MPEP, 
MTEP, naltrexone and citalopram were dissolved in sterile water, while rimonabant was 
dissolved in a suspension of 1% CMC, 0.5% SLS, 0.085% providone, and 0.05% 
antifoam. 
 The food pellets used in this study were 45mg dustless precision pellets (#F0021) 
manufactured by Bio-Serv products (Frenchtown, NJ, USA). 
 
Reinstatement Paradigm.   
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Response Training:  Upon arrival, animals were allowed at least three days to 
habituate to their new environment before testing was begun.  Following the habituation 
period, animals were tested once daily in a 30 min food self-administration session.  
Three 45mg food pellets were placed in the food trough prior to the first test session to 
help animals associate the trough with food delivery.  During all training sessions, 
responses on the right lever delivered one 45mg food pellet and produced the concurrent 
presentation of an audible tone and house light illumination both lasting 2 sec.  
Responses on the right lever were reinforced under a fixed ratio (FR) 1 schedule of 
reinforcement whereby each lever press produced food.  Responding on the left lever 
produced no reinforcer or associated stimuli.  Each session ended when either 50 pellets 
had been delivered or 30 min elapsed, whichever occurred first.    Training continued 
until all animals earned all 50 food pellets within the 30 min session for two consecutive 
sessions.  Any animals that failed to meet this criterion within 7 sessions were excluded 
from the experiment. This value by experiment was relatively low (2.1%). This phase of 
the experiment lasted 3 days. 
Extinction:  The extinction phase began immediately after the subjects had 
successfully acquired the response training criterion noted above and lasted for 4 
consecutive experimental sessions.  During extinction, animals were tested daily for a 30 
min experimental session during which responses on the right lever did not produce food 
pellets or the reinforcer-associated stimuli (i.e. tone and house light).  As during 
acquisition, responding on the left lever produced no reinforcer or food-associated 
stimuli. Animals continued responding under extinction until their responses had 
stabilized (±20%) for three consecutive days.   
Reinstatement:  Following extinction, food reinstatement was evaluated.  In this 
portion of the experiment, subjects were placed in the operant chamber for a 30 min 
experimental session separated into 5 min time bins.  During reinstatement, only the first 
three right lever responses of each 5 min period were reinforced by a 45mg pellet and the 
presentation of the food-associated stimuli.  Subsequent responses on the right lever 
produced only the tone and house light illumination.  As before, responses on the left 
lever were recorded but not reinforced.  Reinstatement sessions ended after 100 right 
lever responses or when 30 min had elapsed, whichever occurred first.   
Second Reinstatement:  In order to best utilize experimental animals, all rats 
were studied under a second reinstatement test.  This phase began with the reacquisition 
of the food self-administration behavior on the day following the initial reinstatement 
session.  During reacquisition, animals were tested once daily using the same parameters 
as the rraining sessions described above.  Animals were tested over 3 to 4 sessions to 
ensure that all subjects responded to criterion, earning the maximum 50 reinforcers for 3 
consecutive sessions.  After reacquisition of responding, the rats entered a second set of 
extinction sessions which continued until responding had stabilized.  Following 
extinction, animals underwent a second reinstatement session identical to the one 
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described above.  This allowed for the testing of a second drug or drug vehicle using the 
same animals.  No additional tests were conducted on these rats.  Thus, in most, but not 
all experiments, the same rats used for one drug or vehicle test, were used again in one 
additional experiment.  A total of 5-9 rats were used for each experimental data point. 
Comparison of Reinstatement Stimuli.  A host of stimuli were evaluated to 
establish the comparative efficacy of these stimuli to reinstate responding after extinction.  
Following extinction, stimuli that might produce relapse to food-seeking were evaluated 
the next day (day 8).  The following stimuli were studied: response-produced 
presentations (FR1) of a) food-associated stimuli (tone + light), b) food alone, c) food 
plus food-associated stimuli, d) food plus food-associated stimuli for the first three 
responses only,  e) foot-shock (0.1 mA, for 100 msec) in the absence of food or food-
associated stimuli, and response-independent food delivery wher food was delivered 
along with food-associated stimuli every 30 sec.  Experimental sessions continued for 60 
min or 100 presentations of stimuli, whichever occurred first. 
 
Fixed Ratio (Maintenance) Paradigm.  In these experiments, rats were maintained under 
a schedule of response-produced food delivery.  Responses were not extinguished or 
reinstated as in the reinstatement conditions described above.  Drug effects under this 
maintenance condition could then be compared to drug effects under the reinstatement 
condition to asses the behavioral specificity of drug effects on reinstated behavior. 
 Food Training: All animals were allowed at least three days to habituate 
to their new environment after arrival to the vivarium before testing was begun.  Animals 
were then trained under the FR1 schedule of food delivery as described above.  Training 
continued until all animals earned all 100 possible reinforcers within the 30 min test 
session for two consecutive sessions.  Any animals that failed to meet this criterion 
within 7 sessions were excluded from the experiment.  This value by experiment was 
relatively low (1.3%).  
 
 Evaluation of Drug Effects:  After training, responding was evaluated in these 
animals following drug administration.  Subjects were placed in the operant chamber for 
30 min and each right lever response was reinforced by a 45mg pellet and the associated 
stimuli just as in the training sessions above.  As before, responses on the left lever were 
recorded but not reinforced.  Each session ended after 100 right lever responses had been 
made or when 30 min had elapsed, whichever occurred first. 
 
Data Analysis.  Data were collected for the mean number of responses. Entry into the 
food trough was not recorded.  A one-way analysis of variance (ANOVA) was performed 
on dose-effect data for each compound. Two-way ANOVA was used to evaluate data 
over experimental sessions (treatment x experimental session).  Significant overall 
ANOVA values were subsequently analyzed by Dunnett’s post-hoc test.   
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RESULTS 
 
Reinstatement of Food-Maintained Responding by Food Presentation and/or by 
Discriminative Stimuli.   
The ability of different stimuli to reinstate responding after extinction was 
examined and the data are shown in figure 1.  Comparing all reinstatement conditions to 
one another resulted in a significant effect of treatment condition [F (5,47) = 16.4, p 
<0.0001).  All stimuli investigated produced reinstatement of responding that was 
significantly greater than responding on the last day of extinction.  The greatest 
reinstatement was produced by response-produced food and response-produced food with 
concurrently-delivered food-associated stimuli.  All other inducers of reinstatement 
produced lower and roughly equivalent levels of responding.  The reinstatement 
condition of response-produced food + food-associated stimuli for the first 3 responses 
was then utilized to evaluate drug effects as reported below. 
Figure 2 illustrates responding under the food self-administration paradigm 
during acquisition, extinction, and reinstatement. All animals successfully acquired the 
lever press response (right lever) and reached criterion of 50 food deliveries within the 30 
min experimental session by day 2 of training.  During acquisition, there were no 
statistical differences across the three groups of rats[F(2,57) = 0.63, p>0.05], across 
experimental sessions [F(2,57) = 0.16, p>0.05], and no group x session interaction 
[F(4,57) = 0.36, p>0.05].   
During extinction, responses on the right lever significantly declined relative to 
responding during the acquisition period with significant differences compared to the last 
day of acquisition by extinction day 2.  Two-way ANOVA confirmed a significant effect 
of experimental session on behavior [F(3,76) = 9.8, p<0.0001).  There were no 
statistically-significant differences in extinction across groups [F(2,76) = 0.32, p>0.05] 
and no session x group interaction [F(6,76) = 0.98, p>0.05].   
Three stimulus configurations were delivered on the day following extinction (day 
8).  There was a significant effect of treatment group on reinstated behavior [F(2,21) = 
8.7, p<0.001).  In this experiment as with the data in figure 1, food-paired stimuli alone 
were sufficient to significantly reinstate extinguished responding (Fig. 2).  Response-
produced food delivery alone (first 3 responses of each 5 min time bin) or response-
produced food in the presence of food-associated stimuli produced large increases in 
responses post extinction.  (Fig. 2).    
 
Reinstatement of Food-Maintained Responding following Drug Administration.  Table 
1 shows the effect of multiple pharmacological agents on the reinstatement of food self-
administration.  Only rimonabant, LY379268, MPEP, and MTEP were effective in 
altering reinstated responding. Clozapine, d-amphetamine, chlordiazepoxide, ABT-431, 
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naltrexone, and citalopram all failed to affect the reinstatement of food self-
administration as evaluated by this paradigm.   
 Along with their effects on reinstatement, each of the compounds was evaluated 
under a FR1 schedule (response maintenance condition) to determine the behavioral 
specificity of any effects observed on reinstatement.  These data are summarized in Table 
1.  Under these conditions, only LY379268 and MTEP altered responding under an FR1 
schedule of reinforcement (response maintenance) with all other tested compounds 
failing to affect mean responding.   
 
Effect of the mGlu5 Receptor Antagonist MTEP on Reinstatement of Food-
Maintained Responding:  Figure 3 (top panel, black bars) illustrates the effect of MTEP 
(3.0 -10.0 mg/kg) on responding following reinstatement.  MTEP significantly 
suppressed response reinstatement [F (3, 26) = 16.64, p < .01] with 5.6 and 10.0 mg/kg 
significantly separating from vehicle control.  
MTEP was also studied in rats responding under FR1 schedules of food delivery 
(response maintenance condition).  MTEP did not significantly affect responding under 
the FR1 schedule (Fig. 3, top panel, checked bars) [F (3, 26) = 2.03, p > 0.05].   
 
Effect of the mGlu5 Receptor Antagonist MPEP on Reinstatement of Food-
Maintained Responding:  Effects of MPEP (3.0 - 10.0 mg/kg) on responding following 
reinstatement is depicted figure 3 (bottom panel, black bars).  As with MTEP, the 5.6 and 
10.0 mg/kg doses suppressed reinstatement with the 3.0 mg/kg failing to effect 
responding when compared to vehicle [F (3, 35) = 10.99, p < .01].  
MPEP did not decrease responding under the response maintenance FR1 schedule 
[F (3, 35) = 1.39, p > .05] even at doses that suppressed response reinstatement (Fig. 3, 
bottom panel, checkered bars).  
 
Effect of the mGlu2/3 Receptor Agonist LY379268 on Reinstatement of Food-
Maintained Responding:  LY379268 significantly reduced responding under the 
reinstatement condition [F (3, 34) = 37.2, p < .01]. Post-hoc testing indicated that the 3.0 
and 5.6 mg/kg doses of LY379268 produced significant (p<0.01) suppression of 
responding while the 1.0 mg/kg dose failed to alter lever pressing (Fig. 4, top panel, 
black bars).   
LY379268 also reduced responding under the response maintenance FR1 
schedule of food delivery [F (3, 17) = 27.7, p < 0.01].  The dose of 5.6 mg/kg produced a 
significant (p<0.01) reduction in responding as compared to vehicle while the lower 
doses of 1.0 and 3.0 mg/kg had no significant effect (Fig. 4, top panel, checkered bars).   
 
Effect of the CB1 Receptor Antagonist Rimonabant on Reinstatement of Food-
Maintained Responding:  Rimonabant (10.0 mg/kg) significantly (p<0.01) reduced 
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reinstated responding [F (1, 14) = 4.73, p < 0.05] (Fig. 4, bottom panel, black bars).  
Rimonabant failed to produce any effect on the maintenance of food-maintained 
responding under the FR1 schedule of response maintenance [F (1, 14) = 0.74, p > 0.05] 
(Fig. 4, bottom panel, checkered bars). 
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DISCUSSION 
Commonalities in behaviors, controlling variables, and biological substrates exist 
across drug- and non-drug reinforcers that initiate and maintain addictions (c.f., 
Chamberlain et al., 2016; Chen et al., 2017; Rogers, 2017; Volkow et al., 2012, 2017).  
For example, presentation of either morphine- or food-associated stimuli increased 
expression of NGFI-B in the medial and lateral portions of the prefrontal cortex (Kelley 
et al., 2005).  Building upon the idea of reinforcer homology, we created a relatively 
rapid and non-surgical method for evaluating drugs for their potential to treat relapse in 
addiction states using food reinforcement.  In contrast to the many weeks generally used 
in reinstatement models, we present data on a new method that generates assay results in 
8 days. 
We first showed that reinstatement of behavior could be induced by a host of 
stimuli.  All experimental conditions investigated produced reinstatement of responding 
that was significantly greater than extinction response levels.  These included stimuli 
associated with the reinforcer of food delivery, the reinforcer itself, and the stressor of 
foot shock.  Thus, stimuli known to induce reinstatement of drug-taking (Shaham et al., 
2003) were effective in reinstating food-seeking behavior in the current model as well. 
A start to the pharmacological validation of the model was also presented here.  
Drugs used for treatment of addiction craving in patients, naltrexone and rimonabant (see 
Introduction for references) were studied.  Rimonabant selectivity reduced relapse to 
food-seeking behavior, whereas naltrexone did not.  The lack of activity of naltrexone in 
this model might point to the lack of firm data on the potential use of naltrexone in 
reducing hunger for food and food craving.  However, the comparative data on 
naltrexone in non-food-based relapse models is also not extensive and there are reports of 
lack of efficacy (c.f., Comer et al., 1993).  Naltrexone is also not markedly effective 
alone in treating obesity (Narayanaswami and Dwoskin, 2017). In contrast, the efficacy 
of rimonabant is congruent with findings with food addictions as well as drug reinforcers 
(see Introduction).  Further pharmacological validation of the current model with positive 
controls will require clinical efficacy of new agents and the firm establishment of 
efficacy of existing agents.  This is a situation faced in the validation of all animal models 
as prefaced in the introduction.   
Although drugs were shown here to attenuate relapse to food-seeking behaviors, 
the mechanisms by which they produced this effect is likely complex.  For example, 
suppression of reinstatement could be generated by the induction of a state distinct from 
the non-drug food-taking state (state-dependency, e.g.,, Self and Choi, 2004).  Arguments 
against state-dependency can be made (e.g., not all drugs suppressed reinstatement and 
FR1 responding was differentially affected by some drugs that reinstated responses). 
Multiple other mechanisms should also be scrutinized and experimentally tested.  For 
example, drug effects on appetite might have influenced the reinstatement process.  If 
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that were the case, one would predict d-amphetamine and rimonabant, appetite 
suppressants, to decrease responding.  However, increases in FR1 responding were 
reported with d-amphetamine and no effect was shown with rimonabant on FR1 
responding.  Although, it is known that drug effects on behavior do not always follow 
motivational theory (c.f., Kelleher and Morse, 1968; Witkin and Katz, 1990), it is 
important to scrutinize all possibilities when exploring new models.   
In addition to rimonabant, two glutamatergic mechanisms that have been 
implicated in relapse (see Introduction for references), mGlu2/3 receptors and mGlu5 
receptors were also investigated.  These receptor mechanisms were explored using 
specific pharmacological ligands, LY379268 (mGlu2/3 receptor agonist) MPEP (mGlu5 
receptor antagonist), and MTEP (mGlu5 receptor antagonist).  All three compounds 
selectively reduced reinstatement of food-seeking behavior.  Some drugs not typically 
associated with relapse prevention were also studied.   Clozapine, d-amphetamine, 
chlordiazepoxide, ABT-431, and citalopram were not effective in reducing relapse to 
food-seeking.  Other compounds that have shown efficacy in attenuating reinstatement of 
behavior by drugs, such as memantine (Popik et al., 2006), were not studied here but 
could be employed in future studies for model validation.  Additional studies are also 
needed with drugs with efficacy in patients (e.g., lorcaserin) (Narayanaswami and 
Dwoskin, 2017) and those that are not. 
In addition to pharmacological specificity, we also began to explore the 
behavioral specificity of drug action.  Theoretically, a drug that reduces reinstatement 
should do so without affecting ancillary behaviors.  For example, if a drug reduced 
reinstatement of food-seeking but also decreased the ability to normally find and eat food, 
this would not be a valuable medicine. We found that for the drugs that reduced 
reinstatement in the present study (rimonabant, MTEP, MPEP, and LY379268), there 
was a separation in doses that decreased reinstated behavior and doses that decreased 
normal ongoing food-maintained behavior.  Work will need to be done to further address 
the question of behavioral specificity.  In the present study, the baseline maintenance 
behavior (FR1) was not identical in all ways to the reinstated behavior – different 
amounts of behavior generated and different schedules of food delivery.   
The data on the glutamatergic ligands also adds to the experimental literature 
suggesting value for glutamatergic mechanisms as potential anti-addiction agents based 
upon neuroanatomical (Childress et al., 1999; Garavan et al., 2000; Grant et al., 1996; 
Kilts et al., 2001; Maas et al., 1998; Wang et al., 1999; Wexler et al., 2001; Tzschentke, 
2001; Tzschentke and Schmidt, 2000) and functional (Cornish and Kalivas, 2000; 
McFarland and Kalivas, 2001; Meil and See, 1997; Richard, 2019) outcomes as well as 
data from reinstatement models with mGlu5 receptor antagonists and mGlu2/3 receptor 
agonists (see Introduction).  We have previously shown that an mGlu5 receptor antagonist 
reduces relapse to food-seeking in wild-type mice but not in mGlu5 -/- mice (Eiler et al., 
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2011).  The utility of this mechanism in food craving might now be added to the list of 
potential therapeutic applications.  
We conclude that the 8-day assay method presented here might provide a method 
for the rapid detection of new pharmacological approaches to the treatment of relapse 
associated with addictions.  Although the model uses food as a reinforcer, the 
pharmacological data at present point to the possibility of generality to addictive 
behaviors as a whole.  The evidence suggests this possibility since drugs (with the 
possible exception of naltrexone) that were active in preclinical relapse models using 
drugs as reinforcers were active in the food-based model studied here.  It should be noted 
that unlike chronic addiction phenomenon for drugs (e.g., Staples et al., 2015) or food 
(Butler and Eckel, 2018; Lee and Dixon, 2017) that generally develop over long periods 
of time and involve neural remodeling, the present model might not recapitulate these 
neuroplasticity dynamics. 
It is well-known that despite commonalities in controlling variables and 
neurobiological substrates across reinforcers as discussed here, different reinforcers also 
control behavior in distinct ways (c.f., Banks, 2017; Martin-Fardon and Weiss, 2017).  
Thus, the likelihood of this model being able to provide precise prediction of drug effects 
across all reinforcer domains should also not be counted on.  Nonetheless,  the ability to 
generalize to multiple relapsing phenomenon is important: there are many stimuli that 
guide addictive behaviors (drugs, gambling, shopping, internet use, etc.) and all have 
been shown to have deleterious impacts on lives.  As with all preclinical models, ultimate 
validation must come from data on the efficacy of compounds in patients.  The medical 
need for improved medicines in this domain is high from both a health (e.g., Brady et al., 
2016) and economic (e.g., Winkler et al., 2017) perspective.   
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TABLE LEGEND 
Table 1.   Summary of the effects of various drugs on reinstatement and 
maintenance of food-maintained responding.   
 
Mechanism Compound Dose (mg/kg) Reinstatement FR1 
Antipsychotic/D2 receptor antagonist chlorpromazine 5.6 NS NS 
Anxiolytic/GABAA receptor potentiator chlordiazepoxide 20 NS NS 
D1 receptor agonist ABT-431 1 NS Not tested 
Indirect dopamine agonist d-amphetamine 3 NS  
CB1 receptor antagonist rimonabant 10  NS 
mGlu2/3 receptor agonist LY379268 1 NS NS 
  3  NS 
  5.6   
mGlu5 receptor antagonist MPEP 3 NS NS 
  5.6  NS 
  10  NS 
mGlu5 receptor antagonist MTEP 3 NS NS 
  5.6  NS 
  10  NS 
Opioid receptor antagonist naltrexone 10 NS NS 
Antidepressant /Selective serotonin 
reuptake inhibitor 
citalopram 3 NS Not tested 
Arrows indicate significant reductions or increases in responding when compared to 
vehicle.  NS: not significantly different than vehicle control values. 
Results of ANOVA for rimonabant, LY379268, MPEP, and MTEP are provided in the 
results section.  One-way ANOVA results for the other compounds in this table are as 
follows: 
Chlorpromazine: Reinstatement [F (1, 16) = 0.64, p > 0.05]; FR1 [F (1, 14) = 0.79, p > 
0.05] 
Chlordiazepoxide Reinstatement [F (1, 16) = 0.48, p > 0.05]; FR1 [F (1, 14) = 0.62, p > 
0.05] 
ABT431: Reinstatement [F (1, 14) = 0.37, p > 0.05]. 
d-Amphetamine: Reinstatement [F (1, 14) = 0.45, p > 0.05]; FR1 [F (1, 16) = 4.2, p < 
0.05] 
Naltrexone: Reinstatement [F (1, 14) = 0.29, p > 0.05]; FR1 [F (1, 14) = 0.41, p > 0.05]. 
Citalopram: Reinstatement [F (1, 16) = 0.61, p > 0.05]. 
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FIGURE LEGENDS 
 
Figure 1.  Effect of various stimuli on the ability to reinstate responding after extinction 
of food maintained responding. Each bar represents the mean (± SEM) of 5-9  rats/group.  
* p<0.05 compared to data of comparable group on the last day of extinction (control: 
C1-C6).   
 
Figure 2.  Acquisition, extinction, and reinstatement of food-maintained responding in 
three separate group of rats.  Each point represents the mean (± SEM) of 5-9 rats/group.  
On day 8, responses produced in separate groups of rats either food alone (filled circle), 
food + food-associated stimuli (unfilled circle), or food-associated stimuli alone 
(triangle).  # p<0.05 compared to data of comparable group on the last day of response 
acquisition.  * p<0.05 compared to the last day of extinction. 
  
Figure 3. Top Panel:  Effect of MTEP (3.0 – 10.0 mg/kg) on the reinstatement of food-
maintained responding (black bars) or on the maintenance of responding under the FR1 
schedule (checkered bars).  Bottom Panel: Effect of MPEP (3.0 – 10.0 mg/kg) on the 
reinstatement of food-maintained responding (black bars) or on the maintenance of 
responding under the FR1 schedule (checkered bars).   All data are shown as mean (± 
SEM) of 5-9 rats/group.  *p< 0.05 compared to vehicle with Dunnett’s post-hoc. 
 
Figure 4. Top Panel: Effect of LY379268 (1.0 – 5.6 mg/kg on the reinstatement of food-
maintained responding (black bars) or on the maintenance of responding under the FR1 
schedule (checkered bars).   Bottom Panel: Effect of rimonabant (10.0 mg/kg) on the 
reinstatement of food-maintained responding (black bars) or on the maintenance of 
responding under the FR1 schedule (checkered bars).   All data are shown as mean (± 
SEM) of 5-9 rats/group.  p< 0.05 **p< 0.01 compared to vehicle with Dunnett’s post-
hoc.  
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Figure 2. 
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Figure 4 
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A medium throughput rodent model of relapse from 
addiction with behavioral and pharmacological specificity 
Highlights 
 
An 8-day rat model of reinstatement is presented using food reinforcement 
 
Rimonabant, LY379268, MTEP, and MPEP suppressed reinstatement 
 
Reinstatment was suppressed at doses without effect on ongoing behavior 
 
Clozapine, d-amphetamine, chlordiazepoxide, ABT-431, naltrexone and citalopram were 
inactive 
 
The model might be useful for screening compounds for addiction-associated relapse 
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